全文获取类型
收费全文 | 585篇 |
免费 | 48篇 |
国内免费 | 24篇 |
专业分类
耳鼻咽喉 | 1篇 |
儿科学 | 47篇 |
妇产科学 | 7篇 |
基础医学 | 77篇 |
口腔科学 | 9篇 |
临床医学 | 52篇 |
内科学 | 107篇 |
皮肤病学 | 31篇 |
神经病学 | 48篇 |
特种医学 | 79篇 |
外科学 | 70篇 |
综合类 | 24篇 |
预防医学 | 25篇 |
眼科学 | 9篇 |
药学 | 40篇 |
中国医学 | 6篇 |
肿瘤学 | 25篇 |
出版年
2024年 | 2篇 |
2023年 | 7篇 |
2022年 | 10篇 |
2021年 | 13篇 |
2020年 | 4篇 |
2019年 | 11篇 |
2018年 | 21篇 |
2017年 | 5篇 |
2016年 | 8篇 |
2015年 | 23篇 |
2014年 | 16篇 |
2013年 | 21篇 |
2012年 | 15篇 |
2011年 | 29篇 |
2010年 | 21篇 |
2009年 | 25篇 |
2008年 | 25篇 |
2007年 | 36篇 |
2006年 | 23篇 |
2005年 | 22篇 |
2004年 | 21篇 |
2003年 | 10篇 |
2002年 | 20篇 |
2001年 | 20篇 |
2000年 | 11篇 |
1999年 | 15篇 |
1998年 | 21篇 |
1997年 | 15篇 |
1996年 | 29篇 |
1995年 | 10篇 |
1994年 | 19篇 |
1993年 | 8篇 |
1992年 | 4篇 |
1991年 | 7篇 |
1990年 | 10篇 |
1989年 | 7篇 |
1988年 | 14篇 |
1987年 | 10篇 |
1986年 | 8篇 |
1985年 | 11篇 |
1984年 | 5篇 |
1983年 | 5篇 |
1982年 | 6篇 |
1981年 | 6篇 |
1980年 | 5篇 |
1978年 | 3篇 |
1977年 | 4篇 |
1976年 | 6篇 |
1975年 | 6篇 |
1972年 | 2篇 |
排序方式: 共有657条查询结果,搜索用时 0 毫秒
1.
SB Miranda† O Lupi‡ E Lucas† 《Journal of the European Academy of Dermatology and Venereology》2004,18(5):622-625
Pityriasis rosea (PR) is a relatively common disease although its aetiology has not yet been identified. It occurs worldwide and there is no racial susceptibility factor. It usually affects teenagers and young adults between 10 and 35 years of age. Typical PR is much easier to diagnose than the rare atypical forms. We report a rare case of vesicular PR in a black woman who had vesicular lesions limited to her palms and soles in addition to regular typical lesions. We devised an efficient oral erythromycin treatment for this patient. 相似文献
2.
3.
Shahan TA Ohno N Pasco S Borel JP Monboisse JC Kefalides NA 《Connective tissue research》1999,40(3):221-232
Previous studies from our laboratories demonstrated that a peptide from the noncollagenous domain of the alpha3 chain of basement membrane collagen (COL IV), comprising residues 185-203, inhibits polymorphonuclear leukocyte activation and melanoma cell proliferation; this property requires the presence of the triplet -SNS- in residues 189-191 (Monboisse et al., J. Biol. Chem., 269, 25475, 1994; Han et al., J. Biol. Chem., 272, 20395, 1997). In the present study, we demonstrate that whole native COL IV and -SNS- containing synthetic peptides (10 microg/ml) added to culture medium inhibit the proliferation of not only melanoma cells, but also breast-, pancreas- and stomach-tumor cells up to 67%, and prostate tumor cells by 15%. ALC-COL IV at 5 microg/ml was shown to inhibit melanoma cell proliferation maximally at 69% and the alpha3(IV)185-203 peptide inhibited proliferation (62%) maximally at 10 microg/ml. Treatment of the alpha3(IV)185-203 peptide with either a specific mAb or a polyclonal antibody, prepared against the sequence alpha3(IV)179-208, decreased the ability of the peptide to inhibit cell proliferation by 97%, while treatment of ALC-COL IV with the same antibodies inhibited proliferation by 44%. Exposure of the above tumor cells to COL IV or the peptides resulted in an increase of intracellular cAMP that was inhibited by prior treatment of the protein with the above antibodies. To investigate the role of cAMP in the inhibition of cell proliferation, cAMP analogs and inhibitors were used. cAMP analogs mimicked the inhibitory effect of the peptide. Rp-cAMPS, a cAMP competitive inhibitor, suppressed the inhibitory effect of ALC-COL IV and of the cAMP analogs. The protein kinase-A inhibitor H-89 blocked the ability of ALC-COL IV and of the alpha3(IV)185-203 peptide to inhibit tumor cell proliferation. These data suggest that ALC-COL IV, through its alpha3(IV) chain, inhibits tumor cell proliferation utilizing a signal transduction pathway which includes cAMP and cAMP-dependent protein kinase(s). 相似文献
4.
5.
Alleles of RUNX2/CBFA1 gene are associated with differences in bone mineral density and risk of fracture. 总被引:4,自引:0,他引:4
Tanya Vaughan Julie A Pasco Mark A Kotowicz Geoff C Nicholson Nigel A Morrison 《Journal of bone and mineral research》2002,17(8):1527-1534
The aim of this study was to determine if DNA polymorphism within runt-related gene 2 (RUNX2)/core binding factor A1 (CBFA1) is related to bone mineral density (BMD). RUNX2 contains a glutamine-alanine repeat where mutations causing cleidocranial dysplasia (CCD) have been observed. Two common variants were detected within the alanine repeat: an 18-bp deletion and a synonymous alanine codon polymorphism with alleles GCA and GCG (noted as A and G alleles, respectively). In addition, rare mutations that may be related to low BMD were observed within the glutamine repeat. In 495 randomly selected women of the Geelong Osteoporosis Study (GOS), the A allele was associated with higher BMD at all sites tested. The effect was maximal at the ultradistal (UD) radius (p = 0.001). In a separate fracture study, the A allele was significantly protective against Colles' fracture in elderly women but not spine and hip fracture. The A allele was associated with increased BMD and was protective against a common form of osteoporotic fracture, suggesting that RUNX2 variants may be related to genetic effects on BMD and osteoporosis. 相似文献
6.
7.
8.
The pathogenesis of diphenylhydantoin-induced pure red cell aplasia was investigated in the case of a 32-year-old man who developed pure red cell aplasia while he was under treatment with diphenylhydantoin. The patient's serum IgG purified from serum drawn at the time of diagnosis suppressed normal allogeneic marrow colony-forming (CFU-E) and burst- forming (BFU-E) and autologous blood BFU-E growth in vitro only in the presence of diphenylhydantoin. This IgG-diphenylhydantoin complex had no effect on CFU-GM growth in vitro. Normal IgG or patient's IgG purified from serum drawn after the remission of red cell aplasia had no effect on erythroid colony formation in vitro in the presence of diphenylhydantoin. The IgG-diphenylhydantoin complex exerted no direct cytotoxic effect on normal marrow erythroblasts, CFU-E, and BFU-E, nor did it interfere with the action of erythropoietin on marrow erythroblasts. These studies suggest that diphenylhydantoin-induced red cell aplasia is immunologically mediated through an IgG inhibitor, which requires the presence of the drug to suppress erythroid colony formation in vitro. This inhibitor seems to exert its effect on erythroid progenitors at or beyond the stage of differentiation of CFU- E, but not on erythroblasts. 相似文献
9.
Alice M. J. Torpy Sharon L. Brennan Mark A. Kotowicz Julie A. Pasco 《Archives of osteoporosis》2012,7(1-2):173-178
Introduction
Osteoporosis poses a significant public health problem for ageing Australians. However, approximately 25?% of Australian adults aged 20?C49?years have osteopenia, a precursor condition to osteoporosis. Despite this, little is known about bone density testing in this age group.Methods
Reasons for referral to dual energy X-ray absorptiometry (DXA) were examined in 2,264 patients aged 20?C49?years, referred in 2001?C2010 to the Geelong Bone Densitometry Service, Geelong Hospital, Victoria. Referral reasons were determined from clinical indication codes derived from patient records. Age, sex and bone mineral density (BMD) T scores were ascertained for each patient.Results
The most common reason for referral for women reflected glucocorticoid use, and for men reflected fracture. Compared to women, men were more likely to have been referred because of minimal trauma fracture or low BMD (41.7 versus 27.1?%, p?<?0.001). No further differences were identified between the sexes, with similar numbers of referral observed for secondary osteoporosis, and monitoring of drug therapy. At the spine, and for all indications, men had a significantly greater BMD deficit compared to women (all p????0.002). After age adjustment, men who were tested due to fracture or glucocorticoid reasons had significantly greater BMD at the total hip (p????0.03). No further associations were seen after age adjustment between referral reason and BMD.Conclusions
Our study presents the first data examining reasons for referral to DXA among Australians aged 20?C49?years. Understanding health service utilisation regarding bone health in young adults is fundamental to understanding future risk, informing effective public health messages and raising awareness of osteoporosis. 相似文献10.
To determine the age- and BMD-specific burden of fractures in the community and the cost-effectiveness of targeted drug therapy, we studied a demographically well-categorized population with a single main health provider. Of 1224 women over 50 years of age sustaining fractures during 2 years, the distribution of all fractures was 11%, 20%, 33%, and 36% in those aged 50-59, 60-69, 70-79, and 80+ years, respectively. Osteoporosis (T score < -2.5) was present in 20%, 46%, 59%, and 69% in the respective age groups. Based on this sample and census data for the whole country, treating all women over 50 years of age in Australia with a drug that halves fracture risk in osteoporotic women and reduces fractures in those without osteoporosis by 20%, was estimated to prevent 18,000 or 36% of the 50,000 fractures per year at a total cost of $573 million (AUD). Screening using a bone mineral density of T score of -2.5 as a cutoff, misses 80%, 54%, 41%, and 31% of fractures in women in the respective age groups. An analysis of cost per averted fracture by age group suggests that treating women in the 50- to 59-year age group with osteoporosis alone costs $156,400 per averted fracture. However, in women aged over 80 years, the cost per averted fracture is $28,500. We infer that treating all women over 50 years of age is not feasible. Using osteoporosis and age (>60 years) as criteria for intervention reduces the population burden of fractures by 28% and is cost-effective but solutions to the prevention of the remaining 72% of fragility fractures remain unavailable. 相似文献